Related Experiment Video
Updated: Oct 5, 2025

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach
Published on: May 7, 2019
Hepatitis C virus and kidney transplantation: Recent trends and paradigm shifts
Guy El Helou1, Colleen Jay2, Marina Nunez3
1Department of Internal Medicine, Division of Infectious Diseases and Global Medicine, University of Florida, Gainesville, FL 32608, United States of America.
Insights
Direct-acting antivirals can now effectively treat Hepatitis C virus (HCV) infection, improving outcomes for kidney transplant patients. Research also explores transplanting kidneys from HCV-viremic donors to uninfected recipients.
Area of Science:
- Nephrology and Transplant Immunology
- Hepatology and Virology
Background:
- Hepatitis C virus (HCV) infection significantly impairs patient and graft survival post-kidney transplantation.
- Recent advancements in direct-acting antivirals (DAAs) offer effective HCV elimination.
- Increased HCV prevalence in donors has led to a rise in HCV-viremic donor to uninfected recipient kidney transplants.
Purpose of the Study:
- To review the current literature on HCV infection in kidney transplantation.
- To discuss the epidemiology, clinical outcomes, and treatment of HCV in transplant recipients.
- To examine the practice and ongoing debates surrounding transplantation from HCV-viremic donors to uninfected recipients.
Main Methods:
- Comprehensive literature search on Hepatitis C virus and kidney transplantation.
- Review of studies on HCV treatment efficacy with direct-acting antivirals.
- Analysis of outcomes data for kidney transplantation involving HCV-viremic donors.
Main Results:
- Direct-acting antivirals demonstrate effectiveness in treating HCV in kidney transplant recipients.
- Transplantation of kidneys from HCV-viremic donors into uninfected recipients is an emerging practice.
- Limited data suggest improved outcomes for treated HCV-infected kidney transplant patients.
Conclusions:
- Effective HCV treatment with DAAs has transformed management in kidney transplant recipients.
- Protocols for transplanting kidneys from HCV-viremic donors require further optimization and debate.
- Additional research with longer follow-up is crucial to fully understand long-term outcomes.
Abstract:
The management of HCV infection in kidney transplantation presents significant challenges. HCV, left untreated, worsens patient and graft survival after kidney transplantation through multiple mechanisms. The field has evolved significantly in recent years, due to the ability to effectively eliminate the virus with direct-acting antivirals. Limited data suggest that current HCV treatment improves outcomes of infected kidney transplant patients. Along with the ability to successfully treat HCV, the increased HCV prevalence among donors has led to transplantation of kidneys from HCV-viremic donors into uninfected recipients. The practice has become increasingly common, but optimization of protocols to guide this practice is currently under debate. We have searched the literature on HCV and kidney transplantation, and review here the epidemiology, clinical outcomes, HCV treatment, and studies on transplantation from positive donor to negative recipient. We also discuss the evolving clinical management paradigms and address unresolved questions, highlighting the need for additional data with longer follow up.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Transplant III: Nursing Management
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Kidney Disease I: Introduction

